All news

Novartis faces fresh patent cliff after trial setbacks

CNBC · RSS · · AI-summarised by FinFlash

Novartis is working to build its next generation of blockbuster medicines after a series of clinical trial setbacks, with disappointing data underscoring the difficulty of replacing revenue lost as older drugs lose patent protection. The Swiss pharma giant is moving past one patent cliff while another looms.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.